Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

Conclusion Although severe acute toxicity did not exceed 30% even at the highest tested dose, nearly half of surviving patients demonstrated grade 3 adverse events at 3 years, which underscores the importance of long-term monitoring of toxicity in trials of radiosensitizing agents.
PMID: 29558281 [PubMed - as supplied by publisher]

Source: Clinical Genitourinary Cancer - March 20, 2018 Category: Cancer & Oncology Authors: Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L, Translational Breast Cancer Research Consortium Tags: J Clin Oncol Source Type: research